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1Molecular Pharmacology, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland, 2 Institute of
Pharmacology and Toxicology, Department of Medicine, University of Zurich, Zurich, Switzerland
Inhibition of the G-protein-coupled receptor kinase 2 (GRK2) is an emerging treatment
approach for heart failure. Therefore, cardio-protective mechanisms induced by
GRK2 inhibition are under investigation. We compared two different GRK2 inhibitors,
i.e., (i) the dual-specific GRK2 and raf kinase inhibitor protein, RKIP, and (ii) the
dominant-negative GRK2-K220R mutant. We found that RKIP induced a strong
sensitization of Gq/11-dependent, heart failure-promoting angiotensin II AT1 receptor
signaling. The AT1-sensitizing function of RKIP was mediated by the RKIP-GRK2
interaction because the RKIP-S153V mutant, which does not interact with GRK2, had
no effect on AT1-stimulated signaling. In contrast, GRK2-K220R significantly inhibited
the AT1-stimulated signal. The in vivo relevance of these major differences between two
different approaches of GRK2 inhibition was analyzed by generation of transgenic mice
with myocardium-specific expression of RKIP and GRK2-K220R. Our results showed
that a moderately increased cardiac protein level of RKIP was sufficient to induce major
symptoms of heart failure in aged, 8-months-old RKIP-transgenic mice in two different
genetic backgrounds. In contrast, GRK2-K220R protected against chronic pressure
overload-induced cardiac dysfunction. The AT1 receptor contributed to RKIP-induced
heart failure because treatment with the AT1 receptor antagonist, losartan, retarded
symptoms of heart failure in RKIP-transgenic mice. Thus, sensitization of the heart
failure-promoting AT1 receptor by the RKIP-GRK2 interaction contributes to heart
failure whereas dominant-negative GRK2-K220R is cardioprotective. Because RKIP is
up-regulated on cardiac biopsy specimens of heart failure patients, the deduced heart
failure-promoting mechanism of RKIP could also be relevant for the human disease.
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INTRODUCTION
The family of G-protein-coupled receptor kinases (GRKs) initiates the process of signal
desensitization by phosphorylation of G-protein-coupled receptors (1, 2). Among different GRKs,
the G-protein-coupled receptor kinase 2 (GRK2) is the most important member of the GRK family
because functions of GRK2 are indispensable, and complete loss of GRK2 in GRK2-knockout mice
is lethal (3). On the other hand, there are multiple lines of evidence, which show that inhibition
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of exaggerated GRK2 activity in experimental models of heart
failure is cardio-protective (4–8). Based on these data, inhibition
of GRK2 appears as a promising treatment approach of heart
failure (9, 10).
Experimental evidence indicates that a major cardio-
protective mechanism induced by GRK2 inhibition relies on re-
sensitization of desensitized beta-adrenoceptors in heart failure
(9, 10). In addition, several other cardio-protective mechanisms
of GRK2 inhibition were deduced, which include improvement
of mitochondrial function and promotion of cardiomyocyte
survival (11, 12). Prevention of cardiomyocyte death by GRK2
inhibition was partially attributed to enhancement of the pro-
survival Raf-Erk pathway (8, 12).
Apart from inhibition of kinase-dependent functions of
GRK2, recent data show that kinase-independent functions of
GRK2 are also important for cardio-protection. In this respect,
the focus lies on the amino-terminal domain of GRK2, which
contains a regulator of G-protein signaling (RGS) domain (13,
14). The RGS domain of GRK2 is functional and inhibits
Gq/11-mediated signaling (13, 14), which is an established
causative factor of myocardial hypertrophy (15). Consequently,
by inhibition of pro-hypertrophic Gq/11-mediated signaling
(15), the RGS domain of GRK2 has documented cardioprotective
activity (16). It is noteworthy that most approaches of GRK2
inhibition leave this cardioprotective RGS domain of GRK2
intact, i.e., the betaARKct, which inhibits GRK2-mediated
receptor phosphorylation by scavenging of Gβγ subunits (4,
5), or ATP-site directed kinase inhibitors such as paroxetine
(7, 17). Also, the kinase-inactive GRK2-K220R mutant, which
acts as a dominant negative GRK2 mutant, has a preserved
amino-terminal RGS domain (18), and shows effective RGS
domain-mediated inhibition of Gq/11-stimulated signaling (12).
But other approaches of GRK2 inhibition target specifically the
amino-terminal domain of GRK2 such as the raf kinase inhibitor
protein, RKIP, which is the alias for phosphatidylethanolamine-
binding protein 1, PEBP1 (19). Consequently, RKIP could also
inhibit the cardioprotective RGS domain of GRK2.
RKIP is an inhibitor of GRK2, which switches from Raf1
to GRK2 by PKC-mediated phosphorylation on serine 153
(19). The serine-153-phosphorylated RKIP interacts with the
amino-terminal domain of GRK2 and thereby blunts GRK2-
mediated phosphorylation of receptor substrates such as the
beta-adrenoceptor (19). On the other hand, by interaction
with the RGS domain-containing amino-terminus of GRK2,
serine-153-phosphorylated RKIP could also interfere with the
cardioprotective Gq/11-inhibitory function of the RGS domain
(19). As a consequence, the RKIP-GRK2 interaction, would
sensitize signaling stimulated by major Gq/11-coupled, heart
failure-promoting GPCRs such as the angiotensin II AT1
receptor (20) by a dual mechanism, which involves GRK2 and
RGS domain inhibition.
Because RKIP is up-regulated on cardiac biopsy specimens of
failing human hearts (21), these potentially detrimental functions
of RKIP are of pathophysiological relevance. We addressed
this issue and found that RKIP strongly enhanced signaling
stimulated by the Gq/11-coupled AT1 receptor in cells. In vivo,
a moderately increased cardiac RKIP level induced by transgenic
RKIP expression under control of the myocardium-specific
alpha-MHC promoter was a sufficient cause for development
of major symptoms of heart failure. For comparison, targeting
of GRK2 by the dominant-negative GRK2-K220R showed RGS-
domain-mediated inhibition of AT1-stimulated signaling in
cells, and cardioprotective activity against chronic pressure-
overload-induced cardiac dysfunction in vivo. In agreement with
a causative role of AT1 receptor sensitization in the cardiac
phenotype triggered by RKIP, inhibition of the AT1 receptor
by the AT1-specific antagonist, losartan, retarded signs of heart
failure in RKIP-transgenic mice. Together our data strongly
suggest that sensitization of AT1 receptor signaling contributes
to RKIP-induced cardiac dysfunction.
MATERIALS AND METHODS
Generation of Transgenic Mice
Different transgenic mouse lines were generated and/or
characterized in frame of this study. For transgenic expression of
RKIP, the cDNA encoding PEBP1 (phosphatidylethanolamine-
binding protein 1, RKIP) was placed under control of the
alpha-myosin heavy chain (alpha-MHC) promoter (8). The
cDNA encoding GRK2-K220R (ADRBK1K220R) was also
inserted into the alpha-MHC plasmid. Plasmid backbone
was removed by Not1 digestion. After pronuclear injection
of transgenic DNA (2 ng/µL) into fertilized oocytes isolated
from super-ovulated B6 (C57BL/6J) or FVB (FVB/NJ) mice,
embryo transfer of 2-cell embryos was performed into 0.5-
day pseudo-pregnant CD-1 foster mice. PCR genotyping of
offspring was performed at an age of 3 to 4 weeks with ear-
punch biopsies. Founder mice of the FO generation with stable
integration of the transgenic DNA into the genomic mouse
DNA were used for further breeding. Different RKIP-transgenic
mouse lines were generated in the B6 (C57BL/6J) background
(C57BL/6Tg(MHCPEBP1)1Sjaa; JAX strain ID 911818), and
FVB (FVB/NJ) background (FVB/NTg(MHCPEBP1)1Sjaa, JAX
strain ID 911819). Tg-GRK2K220R mice were generated in the
B6 background (C57BL/6Tg(MHCADRBK1K220R)1Sjaa; JAX
strain ID 911825). As indicated, phenotyping of male transgenic
mice was performed at an age of 8 months. In addition, 8-week-
old male B6 mice were subjected to 2 months of chronic pressure
overload imposed by abdominal aortic constriction, AAC (22).
At the end of the observation period, AAC-induced chronic
pressure overload was controlled and confirmed by an increased
systolic aortic pressure (>150 mmHg) as determined by invasive
hemodynamic measurement (Micro-Tip R© Catheter Pressure
Transducer 1F, Millar Instruments). The left ventricular ejection
fraction was determined under tribromoethanol anesthesia (250
mg/kg body weight; i.p.; freshly prepared and protected from
light) by M-mode echocardiography in the parasternal long-axis
view with a Vivid 7 echocardiography equipment and a 12
MHz linear array ultrasound transducer (GE Healthcare). Data
were evaluated oﬄine with the EchoPac Pc 3.0 software (GE
Healthcare) using the formula of Teichholz to calculate the left
ventricular ejection fraction (22). Systolic blood pressure was
measured with a PowerLab data acquisition system coupled to a
pulse transducer/cuff (AD Instruments). All animal experiments
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were conducted in agreement with the NIH guidelines, and
reviewed and approved by the local committee on animal care
and use (Cantonal Veterinary office, Zurich).
Whole Genome Microarray Gene
Expression Profiling
For whole genome microarray gene expression profiling,
anesthetized mice (ketamine/xylazine, 100 mg/10 mg/kg) were
perfused with PBS, hearts from transgenic mice (Tg-RKIP, Tg-
GRK2K220R), and non-transgenic B6 controls were isolated,
pulverized under liquid nitrogen, and total RNA was isolated
by the RNeasy Midi kit according to the protocol of the
manufacturer (Qiagen). RNA purity was confirmed by an
absorbance ratio A260/280 of ∼2.0. The absence of RNA
degradation and RNA quality were further controlled by the
presence of bright bands of 18S and 28S ribosomal RNA
in denaturing RNA electrophoresis. The RNA was reverse
transcribed and processed for whole genome microarray
gene expression profiling following the Affymetrix protocol
(GeneChip Expression Analysis Technical Manual, rev. 5,
Affymetrix Inc., Santa Clara, CA, USA). Fragmented and biotin-
labeled cRNA (15 µg/gene chip) in 200 µl of hybridization
solution was hybridized to the microarray gene chip (Mouse
Genome MG430 2.0 Array, Affymetrix) in a hybridization
oven 640 (Affymetrix) for 16 h at 45◦C. After washing and
staining of gene chips with a Fluidics Station 450 (Affymetrix)
according to the GeneChip Expression Analysis Technical
Manual, microarrays were scanned with the GeneChip Scanner
7G (Affymetrix), and signals were processed with a target value
of 300 using GCOS software version 1.4 (Affymetrix). Cardiac
RNA from three mice was pooled for one gene chip, and two
gene chips are presented for each group. Such an approach
is feasible with inbred mouse lines due to negligible intra-
individual variability (23). Probe sets with significantly different
signal intensities were identified by TIGR MeV (p < 0.01,
just alpha, ≥2-fold difference between probe sets with call
present and/or signal intensity ≥100). These selection criteria
were specifically validated for treatment effects (23) and follow
the guidelines of the MicroArray Quality Control (MAQC)
project for the identification of reproducible gene lists (24,
25). Results were similarly obtained with GCOS/RMA-processed
data using GeneSpring GX software (Agilent Technologies Inc.,
Santa Clara, CA, USA). Selected transcripts were analyzed after
reverse transcription by quantitative real time qRT-PCR using a
LightCycler 480 Instrument (Roche). Primers used for qRT-PCR
of PEBP1 expression in Tg-RKIP mice did not amplify the mouse
Pebp1 (PEBP1 forward 5′-GCAGCACCCGCTGCATGTCAC-
3′; PEBP1 reverse 5′-CTCGTCACACTT TAGCGGCCTG-3′).
Microarray gene expression data were deposited to the NCBI
GEO database (accession number GSE 120020).
Immunoblot Detection and
Immunohistology
Cardiac protein levels of RKIP (PEBP1, Pebp1), GRK2, and
Pparg were determined by immunoblot analysis of hearts isolated
from Tg-RKIP and Tg-GRK2K220R mice. The respective non-
transgenic mice (B6 or FVB) were used as controls. Anesthetized
mice (ketamine/xylazine, 100 mg/10 mg/kg) were perfused with
PBS, hearts were isolated and immediately frozen in liquid
nitrogen. For protein detection in immunoblot, hearts were
pulverized under liquid nitrogen, and proteins were extracted
with RIPA buffer supplemented with protease/phosphatase
inhibitors. Pellets from AT1 receptor-expressing HEK cells with
transfection of expressing plasmids encoding RKIP and GRK2
or mock-transfected cells as indicated were similarly extracted.
Particulate material was removed by centrifugation followed
by protein precipitation/delipidation with acetone/methanol
(12:2; final concentration 83%) for 90min at 4◦C. The
precipitate was collected by centrifugation and washed 3 times
with 0.2ml of ice-cold acetone. The pellet was dissolved
in SDS sample buffer containing 2% SDS, 0.1M DTT and
6M urea by incubation for 90min at room temperature.
Samples were stored at −70◦C for further use. Immunoblot
detection of proteins was performed after separation of
proteins by SDS-PAGE and electrophoretic protein transfer to
PVDF membranes. For immunoblot detection of proteins, we
used affinity-purified antibodies or F(ab)2 fragments of the
respective antibodies pre-absorbed on mouse/human serum
proteins. Bound antibody was visualized with F(ab)2 fragments
of peroxidase-coupled secondary antibodies (pre-absorbed on
mouse/human serum proteins) or peroxidase-coupled protein
A followed by chemiluminescent western blot detection (ECL
Plus or ECL Prime; Amersham). Histological analyses were
performed with paraffin-embedded cardiac sections of the
different transgenic mouse lines and compared to non-
transgenic controls (8). Myocyte cross-sectional diameter was
determined by histomorphometrical analysis of hematoxylin-
eosin-stained longitudinal sections of 5µm thickness. The
mean cardiomyocyte cross-sectional diameter (CSD) in the left
ventricular free wall was determined by computerized image
analysis (Image J) by an observer, who was blinded to the
mouse genotype. Cardiomyocyte diameter quantification used
6 different hearts/group with five separate fields of cells on
each heart. A total of 100 cardiomyocytes with centered nuclei
were evaluated per heart. Immunohistological detection of RKIP
was performed on longitudinal cardiac sections after antigen
retrieval with affinity-purified polyclonal antibodies raised
against full-length, recombinant RKIP. Antibody incubation
was performed for 60min at 37◦C in blocking buffer (PBS,
pH 7.4, supplemented with 5% bovine serum albumin, 0.05%
Tween-20), and unbound antibodies were removed by three
washing steps with PBS supplemented with 0.05% Tween
20. After incubation with peroxidase-conjugated secondary
antibody (dilution 1:500, Dianova, Hamburg) and removal of
unbound antibodies by washing steps, bound antibody was
visualized by an enzyme substrate reaction (DAB Enhanced
Liquid Substrate System, Sigma). Myocardial necrosis was
determined by von Kossa staining (Calcium stain kit, modified
Von Kossa No. KT028, Diagnostic Biosystems Pleasanton, CA,
USA). A Leica DMI6000 microscope equipped with a DFC
420 camera was used for imaging of (immuno)-histological
sections.
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FIGURE 1 | RKIP promotes AT1 receptor sensitization whereas GRK2-K220R inhibits AT1-stimulated signaling. (A) Scheme of GRK2 and the amino-terminal RKIP
interaction site (upper panel) compared to the dominant-negative GRK2-K220R mutant (lower panel). (B,C) Total inositol phosphate levels of AT1 receptor-expressing
HEK cells stimulated without (–) or with (+) angiotensin II (100 and 10 nM) and transfected without (–) or with (+) RKIP and RKIP-S153V (B), or GRK2 and
GRK2-K220R (C) as indicated (upper panels). Data are expressed as mean ±s.d. (n = 8; ***p < 0.001 vs. column 2; Tukey’s test).The lower panels show
immunoblots, which detect RKIP (B) and GRK2 (C) proteins of HEK cells expressing the indicated proteins Immunoblot detection of GNB was used as a loading
control (±s.d.; n = 4; ***p < 0.001 vs. mock; Tukey’s test). See also Supplementary Figures 1A,B.
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Antibodies
The study used the following antibodies for immunoblotting and
immunohistology: polyclonal anti-RKIP antibodies were raised
in rabbit against full-length, recombinant RKIP (8); polyclonal
anti-phospho-S153-RKIP antibodies were raised in rabbit against
an epitope in RKIP encompassing phospho-serine-153 (sc-32623;
Santa Cruz Biotechnoloy Inc.); polyclonal anti-GRK2 antibodies
were raised in rabbit against full-length, recombinant GRK2
(ADRBK1) protein expressed in and purified from Sf9 cells
(12); polyclonal anti-Gnb/GNB antibodies were raised in rabbit
against purified GNB (8); polyclonal anti-Pparg antibodies were
raised in rabbit against a peptide encompassing amino acids
8-106 of PPARG (Santa Cruz Biotechnology Inc.); polyclonal
antibodies against phospho-Ser-273 PPARG were raised against
a synthetic phosphopeptide encompassing the phosphorylation
site of serine-273 of PPARG (bs-4888R; BIOSS antibodies).
Biochemical Assays
For lipid analysis, frozen hearts were pulverized under
liquid nitrogen, and cardiac lipids were extracted (26). Gas
chromatography (GC) analysis of cardiac lipids was performed
on a gas chromatograph (Focus, Thermo Scientific) equipped
with a DB-23 column (Agilent J&W). After transesterification of
cardiac lipids, fatty acid methyl esters (FAMEs) were detected by
a flame ionization detector and identified by comparison with
a mixture of commercial FAME reference standards (Supelco
37 component FAME mix, Sigma Aldrich). For quantitative
lipid analysis, an internal standard was included. Cardiac TAG
(triacylglycerol) contents were determined by a commercial kit
(TR0100; Sigma). Cardiac DAG (diacylglycerol) and ceramide
contents were quantified by the DAG kinase method (8, 27). The
urinary albumin to creatinine ratio (ACR) was determined by
commercial kits (BCG albumin assay kit MAK124; creatinine
assay kit MAK080; Sigma). Number of cardiac AT1 receptor
binding sites was determined with cardiac membranes by
radioligand binding assay with Sar1,[125I]Tyr4,Ile8-angiotensin
II (2200 Ci/mmol) in the presence and absence of a 1,000-fold
molar excess of losartan to determine non-specific binding. HEK
cells were cultured and transfected with expression plasmids
encoding the AT1 receptor (AGTR1), GRK2 (ADRBK1),
GRK2-K220R, RKIP (PEBP1), and RKIP-S153V as described
(12, 28). Total cellular inositol phosphate levels were determined
of HEK cells with stable AT1 receptor expression, which
were transfected with the indicated expression plasmids (28).
Endogenously expressed human RKIP (PEBP1) of AT1 receptor-
expressing HEK cells, and transgenic RKIP (PEBP1) of Tg-RKIP
mice were down-regulated by transfection/transduction of
a plasmid/lentivirus with an engineered pre-miRNA, which
targets PEBP1 by RNA interference (RNAi). The following
double-stranded oligonucleotides, which encode an engineered
pre-miRNA targeting human RKIP (PEBP1) by RNAi were
inserted into pcDNA6.2-GW/miR for down-regulation of
endogenous RKIP in HEK cells and pLenti6/V5-Dest Gateway
(Invitrogen) for generation of a lentiviral expression plasmid to
down-regulate human RKIP in Tg-RKIP mice: miPEBP1-top
5′-TGC TGT GTA GAG CTT CCC TGA ATC AAG TTT TGG
CCA CTG ACT GAC TTG ATT CAG AAG CTC TAC A−3′;
and miPEBP1-bottom 5′-CCT GTG TAG AGC TTC TGA ATC
AAG TCA GTC AGT GGC CAA AAC TTG ATT CAG GGA
AGC TCT ACA C−3′. For lentiviral transduction of mice,
a pseudotyped lentivirus was generated as described (8). By
a similar RNAi-mediated approach, endogenously expressed
GRK2 of HEK cells was down-regulated (12). Neonatal mouse
cardiomyocytes were isolated from Tg-RKIP mice, Tg-GRK2-
K220R mice, and non-transgenic B6 controls as described
(8). Cellular cAMP levels of isolated neonatal cardiomyocytes
(without and with stimulation by 100 nM isoproterenol)
were determined using a commercial kit (CA200, Sigma
Aldrich).
Statistical Analysis
Data are presented as mean ± s.d. Statistical significance
between two groups was calculated by the unpaired, two-tailed
Student’s t-test. For comparisons between more than two groups,
analysis of variance followed by a Post-test as indicated was
performed. Statistical significance was set at a p-value of <0.05
unless otherwise stated. Statistical evaluation was performed with
GraphPad PRISM 7.0a.Whole genome gene expression data were
analyzed by TIGR Multi Experiment Viewer MeV.
RESULTS
RKIP Promotes AT1 Receptor Sensitization
Whereas GRK2-K220R Inhibits
AT1-Stimulated Signaling
RKIP interacts with the amino-terminal domain of GRK2 and
thereby blunts the interaction of GRK2 with receptor substrates,
with subsequent inhibition of receptor phosphorylation and
desensitization [Figure 1A and (19)]. The amino-terminal
domain of GRK2 also contains an intact RGS domain
(Figure 1A), which blunts Gq/11-dependent signal transduction
(13, 14). We investigated the impact of RKIP on signaling
mediated by the heart failure-promoting, Gq/11-coupled
angiotensin II AT1 receptor. For in vitro experiments, we used
HEK cells as a model system because these cells are widely
used to study mechanisms of signal transduction, notably
signaling events triggered by the AT1 receptor, GRK2 and RKIP
(12, 19, 28). We found that RKIP led to a significantly enhanced
angiotensin II AT1-stimulated inositol phosphate generation
in HEK cells (Figure 1B). This signal sensitization of the AT1
receptor was mediated by the RKIP-GRK2 interaction because
the RKIP-S153V mutant, which cannot switch from Raf1 to
GRK2 (19), had no effect on the AT1 signal (Figure 1B). As a
control, RKIP and RKIP-S153V protein levels were comparable
(Figure 1B).
In contrast to RKIP, the GRK2-K220R mutant, which acts as a
dominant-negative mutant of GRK2 (Figure 1A), led to a strong
inhibition of the AT1-stimulated signal (Figure 1C). Inhibition
of the Gq/11-coupled AT1 receptor was similarly observed with
wild-type GRK2 (Figure 1C). This experiment confirms that the
Gq/11-inhibitory activity of GRK2 is a kinase-independent effect.
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Physiological RKIP Levels Are Sufficient to
Sensitize AT1-Stimulated Signaling in Cells
We asked whether physiological protein levels of RKIP are
sufficient to sensitize the AT1-stimulated response, and down-
regulated endogenously expressed RKIP by transfection of a
pre-miRNA targeting RKIP (PEBP1) by RNAi. Upon RNAi-
mediated down-regulation of endogenously expressed RKIP, the
AT1-stimulated inositol phosphate generation was significantly
decreased (Figure 2A). As a control, down-regulation of
endogenously expressed RKIP was confirmed by immunoblot
analysis (Figure 2A). This experiment shows that physiological
RKIP levels are sufficient to sensitize the angiotensin II AT1
receptor because down-regulation of RKIP led to a decreasedAT1
response.
We also down-regulated the endogenously expressed GRK2
by RNAi (Figure 2B). In contrast to RKIP, down-regulation of
GRK2 led to a significantly increased AT1-stimulated signal
(Figure 2B). This finding shows that endogenously expressed
GRK2 inhibits the Gq/11-coupled AT1 receptor. Together
these experiments reveal that RKIP sensitizes the heart failure-
promoting AT1 receptor whereas endogenously expressed GRK2
and the kinase-deficient GRK2-K220R mutant inhibit AT1-
stimulated signaling.
Myocardium-Specific Expression of RKIP
Induces Cardiac Dysfunction Whereas
GRK2-K220R Improves Cardiac Function
In view of these major differences between two different
approaches of GRK2 inhibition with RKIP and GRK2-K220R,
we compared the two inhibitors in vivo. We generated transgenic
mice with myocardium-specific expression of RKIP and GRK2-
K220R under control of the alpha-MHC promoter in B6
background (Figures 3A–C). The cardiac RKIP protein levels
of two different RKIP-transgenic mouse lines, Tg-RKIP2 and
Tg-RKIP3, were increased 3.5-fold and 2.9-fold, respectively,
over non-transgenic B6 controls (Figure 3A). RKIP-transgenic
mice were compared with Tg-GRK2K220R mice, which showed
a 3.4 ± 0.46-fold increased cardiac GRK2-K220R protein level
compared to non-transgenic B6 controls (Figure 3B).
We analyzed the cardiac phenotype of 8-months-old
transgenic mice with myocardium-specific expression of RKIP
and GRK2-K220R, respectively (Figure 3C). Eight-months-old
Tg-RKIP mice developed signs of heart failure in the absence
of additional stressors (Figures 3D–I). Heart failure in Tg-
RKIP mice was documented by a significantly decreased left
ventricular ejection fraction of 28.2 ± 4.2% and 37.0 ± 3.6% in
Tg-RKIP2 and Tg-RKIP3 mouse lines, respectively (Figure 3D).
In addition to cardiac dysfunction, echocardiographic data
showed that Tg-RKIP hearts were enlarged with significantly
increased left ventricular end-diastolic (LVEDD) and end-
systolic diameters (LVESD) compared to non-transgenic B6
mice while interventricular septal thickness at diastole (IVSD)
was not significantly different (Figure 3E). The phenotype
of cardiac hypertrophy in Tg-RKIP mice compared to non-
transgenic B6 controls was further documented by an increased
heart-to-body weight ratio (Figure 3F). Histological analysis of
FIGURE 2 | Physiological RKIP levels are sufficient to sensitize AT1-stimulated
signaling in cells. (A,B) Total inositol phosphate levels of AT1
receptor-expressing HEK cells stimulated without (–) or with (+) angiotensin II
(100 nM) and transfected without (–) or with (+) a control pre-miRNA (miCont)
or a pre-miRNA targeting endogenously expressed RKIP (miRKIP) or GRK2
(miGRK2) by RNAi as indicated. Data represent mean ± s.d. (n = 8; **p <
0.01 vs. column 2; Dunnett’s test). The lower panels confirm RNAi-mediated
down-regulation of endogenously expressed proteins by immunoblot
detection of RKIP (A) and GRK2 (B). Data represent mean ± s.d. (n = 4). See
also Supplementary Figures 2A,B.
Tg-RKIP2 hearts confirmed these data and showed a phenotype
of cardiac hypertrophy with dilatation (Figure 3G). Histological
analysis further documented significant cardiac fibrosis and
cardiomyocyte necrosis in Tg-RKIP2 hearts (Figures 3H,I). This
histological characterization of Tg-RKIP mice complements
functional data and shows that cardiac dysfunction in Tg-
RKIP mice was accompanied by severe myocardial damage,
which develops during the pathogenesis of heart failure as a
consequence of maladaptive cardiac remodeling.
In contrast to Tg-RKIP mice, transgenic mice with
myocardium-specific expression of the kinase-inactive
GRK2-K220R mutant had a slightly improved cardiac function
and showed no signs of cardiac hypertrophy (Figures 3D–F).
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FIGURE 3 | Myocardium-specific expression of RKIP induces cardiac dysfunction whereas GRK2-K220R improves cardiac function. (A) Immunoblot detection of
RKIP in non-transgenic B6 and two different Tg-RKIP mouse lines, Tg-RKIP2 and Tg-RKIP3 (±s.d.; n = 3; ***p < 0.001 vs. B6; Dunnett’s test). (B) Immunoblot
(Continued)
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FIGURE 3 | detection of GRK2/GRK2-K220R in non-transgenic B6 and Tg-GRK2K220R mice [±s.d., n = 3 (B6) and n = 5 (K220R); **p = 0.0097]. (C) Scheme of
expression plasmid used for generation of Tg-RKIP and Tg-GRK2K220R mice with myocardium-specific expression of RKIP and GRK2-K220R under control of the
alpha-MHC promoter. (D) Left ventricular ejection fraction (EF) of different eight-months-old transgenic mouse lines compared to age-matched, non-transgenic B6
controls (±s.d., n = 5; ***p < 0.001, and *p < 0.05 vs. B6; Dunnett’s test). (E) Left ventricular end-diastolic diameter (left), left ventricular end-systolic diameter
(middle), and interventricular septal thickness (right) of B6, Tg-RKIP2, Tg-RKIP3, and Tg-GRK2K220R mice (±s.d., n = 5; ***p < 0.001 vs. B6; Dunnett’s test). (F)
Heart-to-body weight ratio of different transgenic lines compared to non-transgenic B6 controls (±s.d.; n = 6; ***p < 0.001 vs. B6; Dunnett’s test). (G) Histological
assessment of cardiac sections from a Tg-RKIP2 mouse, a non-transgenic B6 mouse and a Tg-GRK2K220R mouse. Sections were stained with hematoxylin-eosin
(H&E) and are representative of six mice/group (bar: 2mm). (H,I) Cardiac fibrosis was determined by picrosirius red staining (H), and myocardial necrosis was assessed
by von Kossa stain (I) of Tg-RKIP2 and Tg-GRK2K220R mice compared to non-transgenic B6 mice. Left panels show quantitative data evaluation (±s.d.; n = 6
mice/group; ***p < 0.001 vs. B6; Dunnett’s test), and right panels show representative histological sections (bar: 40µm). See also Supplementary Figures 3A,B.
The histological analysis confirmed the normal phenotype of
Tg-GRK2K220R hearts, which was not different from non-
transgenic B6 controls (Figures 3G–I). Notably, there was
no evidence of cardiac hypertrophy and cardiac dilatation in
Tg-GRK2K220R mice (Figures 3E–G).
Major Symptoms of Heart Failure With
Pulmonary Congestion and Renal
Dysfunction in Tg-RKIP Mice
Cardiac dysfunction of Tg-RKIP mice was accompanied by
major symptoms of heart failure. RKIP-mediated sensitization of
pro-hypertrophic AT1-stimulated signaling in Tg-RKIP2 hearts
could contribute to the significantly enlarged cardiomyocyte
cross-sectional diameter (Figures 4A,B), which is a major
factor accounting for maladaptive remodeling in heart failure.
In agreement with excessive AT1-stimulated signaling and
complementary to human heart biopsy specimens from heart
failure patients (29, 30), the AT1 receptor was down-regulated
in Tg-RKIP2 hearts (Figure 4C). This decrease in cardiac AT1
receptor content could be a direct consequence of RKIP-induced
sensitization of AT1-stimulated signaling (cf. Figure 1), because
AT1-stimulated signaling is a causative factor of AT1 down-
regulation (31, 32). In contrast, Tg-GRK2K220R mice did not
show cardiomyocyte hypertrophy (Figures 4A,B). Moreover,
transgenic GRK2-K220R expression did not lead to decreased
cardiac AT1 receptor levels (Figure 4C).
Symptoms of heart failure with severe cardiac dysfunction
in Tg-RKIP2 mice were accompanied by an increased systolic
blood pressure (Figure 4D). Concomitantly, histological lung
sections of Tg-RKIP2 mice showed signs of pulmonary
congestion with alveolar septal thickening, which was absent
in healthy, non-transgenic B6 controls, and Tg-GRK2K220R
mice (Figure 4E). Pulmonary congestion was confirmed by
an increased lung weight and lung-to-body weight ratio of
Tg-RKIP2 mice compared to B6 and Tg-GRK2-K220R mice
(Figure 4F, Supplementary Figure 4). Congestive heart failure
was further documented by a significantly increased body weight
of Tg-RKIP2 mice (Figure 4G). In addition, heart failure in
Tg-RKIP2 mice led to symptoms of renal insufficiency with
significant proteinuria (Figure 4H). Taken together, a moderately
increased cardiac RKIP level is a sufficient cause for the
development of major systemic symptoms of chronic congestive
heart failure in aged Tg-RKIP mice.
Up-Regulation of Heart Failure-Related
Pparg Target Genes in Tg-RKIP Hearts
We performed cardiac whole genome microarray gene
expression profiling to analyze mechanisms underlying the
different phenotype caused by transgenic expression of two
GRK2 inhibitors, RKIP and GRK2-K220R (Figure 5A).
Microarray gene expression analysis identified highly up-
regulated genes (≥6-fold) in Tg-RKIP hearts compared to
non-transgenic B6 controls (Figure 5B). Most of these highly
up-regulated genes are targets of the adipogenic and heart
failure-promoting transcription factor, peroxisome proliferator-
activated receptor-gamma, Pparg, and have documented
relationship to heart failure (Figure 5B). In contrast to Tg-
RKIP hearts, transgenic expression of GRK2-K220R did
not up-regulate any of these heart failure-promoting genes
(Figure 5B).
Activation of Pparg, and Cardiotoxic Lipid
Load in Tg-RKIP but Not in Tg-GRK2K220R
Hearts
The up-regulation of Pparg targets was accompanied by a
significantly decreased phosphorylation of Pparg on serine-273
in Tg-RKIP hearts (Figure 6A). This finding is relevant because
dephosphorylation of Pparg on serine-273 leads to an enhanced
Pparg transcriptional activity (8, 33). In contrast, Pparg was
not activated in Tg-GRK2K220R hearts, and the content of
serine-273-phosphorylated Pparg in Tg-GRK2K220R hearts was
comparable to B6 control level (Figure 6A).
Together with an enhanced activation of the adipogenic Pparg,
Tg-RKIP hearts had an increased cardiac protein content of the
major palmitate-synthesizing enzyme and Pparg target, fatty acid
synthase, Fasn (Figures 6B,C).
Lipid analysis showed that cardiac lipid contents of palmitate,
TAG (triacylglycerol), DAG (diacylglycerol), and ceramide
were also significantly higher in Tg-RKIP hearts compared to
non-transgenic B6 control hearts and Tg-GRK2K220R hearts
(Figures 6D–H). In addition to palmitate, DAG and ceramide
are also cardiotoxic lipid species, which could contribute to
cardiac degeneration and cardiomyocyte loss in Tg-RKIP hearts
(8, 27, 34).
RKIP Induces Symptoms of Heart Failure in
FVB Background
Because cardiac effects induced by RKIP in mice could depend
on the genetic background (35), we generated transgenic
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FIGURE 4 | Major symptoms of heart failure with pulmonary congestion and renal dysfunction in Tg-RKIP mice. (A,B) Cardiomyocyte cross-sectional diameter was
determined with histological cardiac sections of B6, Tg-RKIP2, and Tg-GRK2K220R mice (A). (B) Shows quantitative data evaluation. Sections were stained with
hematoxylin and eosin (H&E) and are representative of six mice each (bar: 20µm). (C,D) Cardiac AT1 receptor content (C), and systolic blood pressure (D) in B6,
Tg-RKIP2 and Tg-GRK2K220R mice. (E) Histological lung sections show heart failure-related lung remodeling with chronic pulmonary congestion and thickening of
alveolar septa in Tg-RKIP2 mice compared to healthy non-transgenic B6 and Tg-GRK2K220R mice. Sections were stained with hematoxylin and eosin (H&E) and are
representative of six mice each (bar: 40µm). (F) Increased lung weight of Tg-RKIP2 compared to B6 and Tg-GRK2K220R mice. (G,H) Increased body weight (G),
and renal insufficiency with proteinuria (H) of Tg-RKIP2 mice compared to non-transgenic B6 and Tg-GRK2K220R mice. Data represent the mean ±s.d. [n = 6; *p <
0.05 vs. B6; **p < 0.01 vs. B6 (B,D,G) and K220R (B,C,D,G); ***p < 0.001 vs. B6 and K220R; Tukey’s test]. See also Supplementary Figure 4.
mice with a moderately increased cardiac RKIP protein
level in the FVB background (Figure 7A). Two different
transgenic lines were generated, which showed 2.7 ± 0.3-
fold and 3.3 ± 0.4-fold increased cardiac RKIP protein
levels over the non-transgenic FVB control (Figure 7A).
Immunohistological analysis confirmed the increased
cardiac RKIP protein content in an 8-months-old Tg-
RKIP heart compared to the non-transgenic FVB control
(Figure 7B).
Tg-RKIP mice with FVB background developed cardiac
hypertrophy, which was detected by an increased heart-to-body
weight ratio of 8-months-old mice (Figure 7C). Concomitantly,
Tg-RKIP mice with FVB background showed symptoms of
heart failure, which was documented by a severely decreased
left ventricular ejection fraction of 30.4 ± 3.5% and 25.1
± 4.7% in Tg-RKIP1 and Tg-RKIP2 mice (Figure 7D).
Echocardiographic data confirmed that Tg-RKIP mice with FVB
background had significant cardiac hypertrophy at an age of
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FIGURE 5 | Up-regulation of heart failure-related Pparg target genes in
Tg-RKIP hearts. (A,B) Cardiac whole genome microarray gene expression
profiling (A) identified highly up-regulated probe sets (≥6-fold up-regulation
compared to B6 with p < 0.01) in Tg-RKIP hearts (B, upper panel). None of
these probe sets was significantly regulated in Tg-GRK2K220R hearts (B,
lower panel). Gene expression data are expressed as -fold of B6 (±s.d., n = 2
gene chips/group with total RNA isolated from n = 3 hearts/gene chip). Highly
up-regulated genes (≥6-fold up-regulation in Tg-RKIP hearts compared to B6
hearts; p < 0.01; with call present and/or signal intensity ≥100) in Tg-RKIP
hearts have documented relationship to heart failure (HF), are Pparg targets
[(*): Pparg)], and/or are induced by Pparg serine-273 phosphorylation
(*:Pparg-pS273).
8 months (Figure 7E). Cardiac enlargement was documented
by significantly increased left ventricular end-diastolic and end-
systolic diameters of Tg-RKIP compared to non-transgenic
FVB mice (Figure 7E). As a control, interventricular septal
thickness was not significantly different between study groups
(Figure 7E).
Histological assessment of hearts from two different RKIP-
transgenic mouse lines in FVB background complemented
this phenotype and showed massive cardiac hypertrophy with
dilatation (Figure 7F). Histomorphological analysis confirmed
the phenotype of cardiomyocyte hypertrophy by a significantly
increased cardiomyocyte cross-sectional diameter in Tg-RKIP
mice compared to non-transgenic FVB mice (Figure 7G).
Similarly to Tg-RKIP mice with B6 background (cf. Figure 4),
aged Tg-RKIP mice with FVB background progressed to chronic
congestive heart failure with a significantly elevated systolic
blood pressure, proteinuria and an increased body weight with
pulmonary congestion, which was documented by an increased
lung weight and lung-to-body weight ratio (Figures 7H–J).
The RKIP-induced cardiac hypertrophy and cardiac
dysfunction were (partially) prevented by down-regulation
of RKIP with lentiviral transduction of an miRNA targeting
the RKIP (PEBP1) by RNA interference (Figures 7K,L). These
experiments confirm that the heart failure phenotype in Tg-
RKIP mice was caused by transgenic expression of RKIP. The
data also indicate that heart failure symptoms induced by an
increased cardiac RKIP level can be counteracted by RKIP
down-regulation. Because RKIP levels are increased in failing
human hearts (21), this finding could be relevant to the human
disease.
RKIP Promotes Cardiac Lipid Overload in
FVB Background
In addition to symptoms of chronic congestive heart failure,
Tg-RKIP mice with FVB background also developed cardiac
lipid overload (Figures 8A–E). Analysis of cardiac fatty acid
composition by gas chromatography (GC) indicated that
palmitate was the major lipid in Tg-RKIP hearts (Figures 8A,B).
Other cardiotoxic lipid species such as ceramide and DAG
were also significantly increased in Tg-RKIP hearts with FVB
background (Figures 8D,E). Together these findings show that
a moderately increased cardiac RKIP protein level is sufficient
to promote symptoms of congestive heart failure, cardiac
hypertrophy with dilatation and cardiotoxic lipid load in two
different genetic backgrounds, i.e., B6 and FVB.
RKIP and GRK2-K220R Act as GRK2
Inhibitors in vivo
RKIP is a dual-specific inhibitor of GRK2 and the Raf-Erk1/2 axis
(19). By PKC-mediated phosphorylation on serine-153, RKIP
switches from Raf1 to GRK2 (19). Because the PKC-activating
DAG was strongly increased in Tg-RKIP hearts, we investigated
whether RKIP acted as GRK2 inhibitor in vivo, in Tg-RKIP mice
with signs of heart failure. In agreement with an increased DAG
load, immunoblot detection revealed a strongly increased content
of serine-153-phosporylated RKIP in Tg-RKIP hearts compared
to non-transgenic B6 controls (Figure 9A).
The serine-153 phosphorylation-dependent transformation of
RKIP into a GRK2 inhibitor was accompanied by sensitization
of cAMP signaling in isolated cardiomyocytes upon stimulation
by the beta-adrenoceptor agonist, isoproterenol, (Figure 9B).
In addition, sensitized cAMP signaling was also detected in
vivo by a significant up-regulation of the cAMP-inducible gene,
Ttc14 [tetratricopeptide repeat protein 14; (36)], (Figure 9C).
RKIP-mediated sensitization of cAMP signaling in Tg-RKIP
cardiomyocytes and hearts was comparable to effects seen with
the dominant-negative GRK2-K220Rmutant in Tg-GRK2K220R
cardiomyocytes and hearts (Figures 9B,C). Taken together, RKIP
acts as GRK2 inhibitor in vivo and mediates sensitization of
cAMP signaling similarly as the dominant-negative GRK2-
K220R mutant.
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FIGURE 6 | Activation of Pparg, and cardiotoxic lipid load in Tg-RKIP but not in Tg-GRK2K220R hearts. (A) Immunoblot detection of Pparg phosphorylated on
serine-273 (pS273-Pparg) in Tg-RKIP, non-transgenic B6 and Tg-GRK2K220R hearts (±s.d.; n = 4 hearts/group; **p < 0.01 vs. B6 and K220R; Tukey’s test). The
lower panel shows the total cardiac Pparg protein content. (B,C) Immunoblot detection of Fasn in Tg-RKIP, non-transgenic B6 and Tg-GRK2K220R hearts (±s.d.; n
= 3 hearts/group; **p < 0.01 vs. RKIP; Tukey’s test). (D) GC analysis of cardiac lipids of Tg-RKIP, Tg-GRK2K220R, and non-transgenic B6 hearts. (E-H) Cardiac lipid
analysis detects increased cardiac contents of palmitate (E), TAG (F), DAG (G), and ceramide (H) in Tg-RKIP hearts (±s.d.; n = 7; ***p < 0.001 vs. RKIP; Dunnett’s
test). See also Supplementary Figures 5A–C.
Concordant Gene Regulation in Tg-RKIP
and Tg-GRK2K220R Hearts
We analyzed the impact of GRK2 inhibition by RKIP and
GRK2-K220R on cardiac gene expression. Whole genome
microarray gene expression profiling data showed concordant
gene regulation in Tg-RKIP and Tg-GRK2K220R hearts
(Figures 10A,B). Notably, 46% of all genes regulated by the
dominant-negative GRK2-K220R mutant in Tg-GRK2K220R
hearts were also concordantly regulated by RKIP in Tg-
RKIP hearts (Figure 10A). These data further support the
notion that moderate transgenic expression levels of RKIP and
GRK2-K220R induce comparable GRK2 inhibition in transgenic
mice.
Dominant-Negative GRK2-K220R Retards
Chronic Pressure Overload-Induced
Cardiac Dysfunction
We asked whether GRK2-K220R was cardio-protective in a
model of heart failure induced by chronic pressure overload
imposed by abdominal aortic constriction, AAC. As a control
for cardioprotective GRK2 inhibition, we used Tg-GRKInh
mice with myocardium-specific expression of a cardioprotective
GRK2-inhibitory peptide derived from the first intracellular
loop of the beta2-adrenoceptor, which is known to retard AAC-
induced cardiac dysfunction (8, 12). Systolic aortic pressure of B6,
Tg-GRK2K220R and Tg-GRKInh mice was comparable under
basal conditions (Figure 11A). At the end of the observation
period, AAC-induced chronic pressure overload was controlled
and confirmed by a significantly increased systolic aortic pressure
(>150 mmHg), which was not different between study groups
(Figure 11A). The transgenic expression of dominant-negative
GRK2-K220R in Tg-GRK2K220R mice significantly retarded the
development of cardiac dysfunction induced by 8 weeks of AAC
compared to non-transgenic B6 controls (Figures 11B,C). The
cardioprotective effect of transgenic GRK2-K220R expression
was comparable to GRK2 inhibition by transgenic expression
of GRKInh (Figures 11B,C). Echocardiographic data further
documented that inhibition of GRK2 by GRK2-K220R and
GRKInh significantly inhibited the development of AAC-
induced dilative cardiac hypertrophy, i.e., the left ventricular
end-diastolic and end-systolic dimensions were significantly
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FIGURE 7 | RKIP induces symptoms of heart failure in FVB background. (A)
Cardiac RKIP protein levels were determined in Tg-RKIP1, Tg-RKIP2 and
non-transgenic FVB mice by immunoblot detection (±s.d.; n = 8; ***p < 0.001
vs. FVB; Dunnett’s test). (B) Immunohistological localization of RKIP on cardiac
sections from an 8-months-old Tg-RKIP1 mouse and an age-matched
non-transgenic FVB mouse (bar: 2mm; nuclei were stained with hematoxylin,
HE). Immunohistology is representative of four hearts/group. (C,D)
Heart-to-body weight ratio (C), and cardiac left ventricular ejection fraction (D)
of 8-months-old Tg-RKIP1, Tg-RKIP2 and non-transgenic FVB mice [±s.d.; n
= 6 (C), and n = 5 (D); ***p < 0.001 vs. FVB; Dunnett’s test]. (E)
Echocardiographic determination of left ventricular end-diastolic diameter (left),
left ventricular end-systolic diameter (middle), and interventricular septal
thickness (right) in 8-months-old Tg-RKIP1, Tg-RKIP2 and non-transgenic
(Continued)
FIGURE 7 | FVB control mice (±s.d.; n = 5; ***p < 0.001 vs. FVB; Dunnett’s
test). (F) Histological analysis of cardiac sections shows cardiac hypertrophy
with dilatation in Tg-RKIP1 and Tg-RKIP2 hearts. (G). Cardiomyocyte
cross-sectional diameter (G), systolic blood pressure (H), and urinary albumin
to creatinine ratio, ACR (I) in Tg-RKIP1, Tg-RKIP2, and non-transgenic FVB
mice. (J) Increased body weight (left), lung weight (middle), and lung-to-body
weight ratio (right) in Tg-RKIP1 and Tg-RKIP2 mice compared to
non-transgenic FVB mice (±s.d.; n = 6; *p < 0.05; **p < 0.01; ***p < 0.001
vs. FVB; Dunnett’s test). (K,L) 4 weeks of RKIP down-regulation by lentiviral
transduction of an miRNA targeting RKIP by RNAi retards the development of
cardiac dysfunction in 10-week-old (10w) Tg-RKIP2 mice (K). Panel (L)
documents the down-regulation of cardiac RKIP (PEBP1) expression in
miRKIP-transduced Tg-RKIP2 mice by qRT-PCR (±s.d.; n = 5; ***p < 0.001,
**p < 0.01, and *p < 0.05 vs. FVB; Dunnett’s test). See also
Supplementary Figure 6.
FIGURE 8 | RKIP promotes cardiac lipid overload in FVB background. (A–E)
GC analysis of cardiac lipids (A), cardiac palmitate (B), TAG (C), ceramide (D),
and DAG (E) contents in 8-months-old Tg-RKIP2 mice with FVB background
compared to age-matched non-transgenic FVB control mice (±s.d.; n = 6;
***p < 0.001). See also Supplementary Figure 7.
smaller in Tg-GRK2K220R and Tg-GRKInh mice compared
to non-transgenic B6 mice whereas the interventricular septal
thickness was not significantly different between study groups
(Figures 11D–F). Together these findings present strong
evidence that inhibition of GRK2 by dominant-negative GRK2-
K220R exerts protection against cardiac dysfunction induced by
chronic pressure overload.
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FIGURE 9 | RKIP and GRK2-K220R act as GRK2 inhibitors in vivo. (A) Immunoblot detection of RKIP phosphorylation on serine-153 and total cardiac RKIP content
in 8-months-old Tg-RKIP compared to non-transgenic B6 hearts (±s.d.; n = 5 Tg-RKIP; n = 4, B6). (B,C) Sensitization of the isoproterenol-stimulated cAMP
response in neonatal cardiomyocytes isolated from Tg-RKIP and Tg-GRK2K220R mice compared to non-transgenic B6 cardiomyocytes (B), and increased cardiac
expression of the cAMP-inducible gene, Ttc14, in Tg-RKIP, and Tg-GRK2K220R hearts (C). Data represent mean ±s.d. (n = 6, B; n = 3, C; ***p < 0.001 vs. B6;
Dunnett’s test). See also Supplementary Figure 8.
FIGURE 10 | Concordant gene regulation in Tg-RKIP and Tg-GRK2K220R hearts. (A,B) Whole genome microarray gene expression profiling was performed with
8-months-old Tg-RKIP2 and Tg-GRK2-K220R hearts compared to non-transgenic B6 hearts. Probe sets with significantly different signal intensity (with call present
and/or signal intensity >100) were identified with p < 0.01, and ≥2-fold difference compared to B6. The Venn diagram illustrates the number of concordantly
regulated genes between Tg-RKIP and Tg-GRK2K220R hearts (A). Representative probe sets (B) show comparable up-regulation of concordantly regulated genes in
Tg-RKIP and Tg-GRK2K220R hearts (±s.d.; n = 2 gene chips/group with n = 3 hearts pooled for one gene chip; ***p < 0.001, **p < 0.01 vs. B6; Dunnett’s test).
Inhibition of the AT1 Receptor Retards
RKIP-Induced Symptoms of Heart Failure
We finally investigated whether the AT1 receptor contributed
to RKIP-induced symptoms of heart failure in vivo. To
address this question, we treated Tg-RKIP mice for 3 months
with the AT1-specific antagonist, losartan, at a dose of 5
mg/kg/day. The applied dose of losartan does not alter
systolic blood pressure in mice (37). Treatment with losartan,
significantly retarded the development of RKIP-induced
cardiac hypertrophy as evidenced by a significantly decreased
heart-to-body weight ratio, the histological assessment, and
the histomorphological analysis of cardiomyocyte size
(Figures 12A–C). Concomitantly, losartan treatment led to
an improved cardiac function, which was documented by
a significantly increased left ventricular ejection fraction
(Figure 12D). Echocardiographic data further documented that
inhibition of the pro-hypertrophic AT1 receptor by losartan
treatment counteracted the phenotype of cardiac hypertrophy
in Tg-RKIP mice (Figure 12D). Together these data provide
strong evidence that sensitization of AT1 receptor signaling
contributes to RKIP-induced cardiac hypertrophy and cardiac
dysfunction.
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FIGURE 11 | Dominant-negative GRK2-K220R retards chronic pressure
overload-induced cardiac dysfunction. (A) Systolic aortic pressure of B6,
Tg-K220R and Tg-GRKInh mice under basal conditions and at the end of the
observation period after 2 months of AAC (±s.d.; n = 6; ***p < 0.001 vs. B6;
Dunnett’s test). (B) Representative echocardiographic images in 2D mode
(upper) and M-mode (lower) of B6, Tg-GRK2K220R and Tg-GRKInh mice with
2 months of chronic pressure overload imposed by AAC. (C–F) Left ventricular
ejection fraction (C), interventricular septal thickness (D), LVEDD (E) and
LVESD (F) were determined by echocardiography of B6, Tg-GRK2K220R and
Tg-GRKInh mice at the end of the observation period after 8 weeks of AAC
(±s.d.; n = 6; ***p < 0.001; Dunnett’s test).
DISCUSSION
In this study, we found that kinase-inactive GRK2K220R
improves cardiac performance under basal conditions and exerts
protection against chronic pressure overload-induced cardiac
dysfunction. These findings with the GRK2-K220R mutant
FIGURE 12 | Inhibition of the AT1 receptor retards RKIP-induced symptoms of
heart failure. (A–C) Treatment for 3 months with the AT1 antagonist, losartan,
retards the development of RKIP-induced cardiac hypertrophy in 8-month-old
Tg-RKIP mice with FVB background as evidenced by a decreased
heart-to-body weight ratio (A), histological analysis (B; bar: 2mm), and
cardiomyocyte cross-sectional diameter (C; bar 20µm). Data represent mean
± s.d.; n = 4 (A,C). Sections were stained with hematoxylin-eosin (H&E) and
are representative of four mice/group (B,C). (D) Left ventricular ejection
fraction (left), left ventricular end-diastolic diameter (middle), and left ventricular
end-systolic diameter (right) of Tg-RKIP mice without and with losartan
treatment were determined by echocardiography (±s.d.; n = 4).
reflect the in vivo effects of a kinase-inhibited GRK2, which
can be similarly achieved by a small molecule GRK2 inhibitor.
In this respect our data with the kinase-inactive GRK2-K220R
extend previous studies on the cardioprotective function of
GRK2 inhibition, which is documented by different approaches
of GRK2 inactivation, e.g., GRK2 deficiency (6), transgenic
expression of the Gβγ-scavenging betaARKct (5, 9), the beta2-
adrenoceptor-derived peptide, GRKInh (8, 12), and inhibition of
GRK2 by an ATP-site-directed inhibitor (7).
Our study also shows that not all approaches of GRK2
inhibition are cardioprotective. In contrast to cardioprotective
GRK2 inhibition with kinase-inactive GRK2-K220R, transgenic
expression of the dual-specific GRK2 and Raf-Erk1/2
axis inhibitor, RKIP, promoted signs of heart failure, i.e.,
cardiac hypertrophy, cardiac dilatation and cardiotoxic
lipid load. In addition, symptoms of chronic congestive
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heart failure were evident in Tg-RKIP mice as documented
by pulmonary congestion with increased lung and body
weight, kidney insufficiency with proteinuria, and elevated
systolic pressure. RKIP-induced signs of heart failure were
similarly observed in two different genetic backgrounds, i.e., B6
and FVB.
Signs of heart failure developed in RKIP-transgenic mice
despite of significant GRK2 inhibition. Experimental data
showed that GRK2 inhibition-induced sensitization of the cAMP
signal was comparable between Tg-RKIP and Tg-GRK2K220R
cardiomyocytes and hearts. Also, the phosphorylation of RKIP on
serine-153 was significant in Tg-RKIP hearts, which is required
for RKIP to act as GRK2 inhibitor. Nevertheless, the GRK2-
inhibitory activity of RKIP was insufficient to protect against
RKIP-induced heart failure.
In this study, several lines of evidence are presented, which
show that sensitization of the AT1 receptor contributes to the
observed RKIP-induced symptoms of heart failure. (I) RKIP
led to increased AT1 receptor-stimulated inositol phosphate
levels in cells. This AT1-sensitization was mediated by the
RKIP-GRK2 interaction because the RKIP-S153V mutant, which
cannot switch from Raf1 to GRK2, did not sensitize the AT1
receptor response. (II) RNAi-mediated down-regulation of RKIP
demonstrated that endogenously expressed RKIP levels were
sufficient to sensitize the AT1-stimulated signal. (III) Tg-RKIP
mice with symptoms of heart failure showed down-regulation
of the cardiac AT1 receptor content, which could be triggered
by RKIP-mediated AT1 receptor sensitization because excessive
AT1-mediated signaling down-regulates AT1 (31, 32). In this
respect, Tg-RKIP mice resemble human patients with heart
failure (29, 30). (IV) Tg-RKIP mice with myocardium-specific
RKIP expression developed cardiac hypertrophy with dilatation,
and cardiac dysfunction, and these symptoms of heart failure
were retarded by treatment with the AT1-specific antagonist,
losartan.
In addition to the heart failure-promoting effect of RKIP-
triggered AT1 receptor sensitization, which was attributed
to the RKIP-GRK2 interaction, symptoms of RKIP-induced
heart failure could be aggravated by additional functions of
RKIP. Notably, the severity of RKIP-induced symptoms of
heart failure could be a consequence of the dual activity
of RKIP as GRK2 and Raf1-Erk1/2 axis inhibitor. While
AT1 receptor sensitization is largely mediated by the RKIP-
GRK2 interaction, the development of cardiotoxic lipid load
is attributed to Raf-Erk1/2 pathway inhibition, which leads
to heart failure-promoting and adipogenic Pparg activation
by inhibition of Pparg phosphorylation on serine-273 (8,
33). As a consequence, cardiotoxic lipid load occurs with
accumulation of the PKC-activating DAG, which accounts
for RKIP serine-153 phosphorylation and the RKIP-GRK2
interaction. The ensuing RKIP-GRK2 interaction not only
restores the beta-adrenoceptor responsiveness but also triggers
cardiotoxic AT1 receptor signaling. In addition, DAG-mediated
activation of PKC is per se an independent contributor to heart
failure (38).
Exaggerated cardiotoxic Gαq/11-stimulated calcium signaling
seems to be a specific feature of RKIP because RKIP
shields the amino-terminal domain of GRK2, which contains
a cardioprotective and Gαq/11-inhibitory RGS domain (13,
14). In contrast to RKIP, established cardioprotective GRK2
inhibitors do not interfere with this RGS domain of GRK2.
ATP-site-directed GRK2 inhibitors such as paroxetine, inhibit
the kinase activity of GRK2 but leave kinase-independent
functions of GRK2 intact, e.g., mediated by the Gαq/11-
inhibitory RGS domain. Also, the betaARKct inhibits GRK2
by Gβγ subunit scavenging but retains the activity of the RGS
domain (4).
The heart failure-promoting activity of RKIP in transgenic
mouse models could also be relevant for the human disease
because cardiac biopsy specimens from heart failure patients
have an increased cardiac RKIP content (21). Notably, RKIP
expression levels in several transgenic mouse models with two
different genetic backgrounds, were comparable to the increased
RKIP level found on human heart biopsy specimens of heart
failure patients (21). Because down-regulation of an increased
RKIP level in transgenic mice retarded the development of
heart failure, RKIP inhibition could be considered as a potential
target for development of a pharmacological treatment approach
of heart failure. The recently elucidated beneficial and cell-
protective side-effect profile of RKIP deficiency and/or RKIP
inhibition further supports such a concept (39).
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